Search research articles
Contact Us
Filters
Showing results (171-180 of 195) with videos related to
Page
of 20
Sort By:
Frontiers in Immunology
|
December 3, 2025
Case Report: Durable response to tumor-infiltrating lymphocyte therapy in a patient with metastatic melanoma and chronic lymphocytic leukemia/small lymphocytic lymphoma
Lilit Karapetyan, Joel Kuriakose, Matthew C Perez, et al.
Bone Marrow Transplantation
|
August 20, 2021
ASTCT, CIBMTR, and EBMT clinical practice recommendations for transplant and cellular therapies in mantle cell lymphoma
Pashna N Munshi, Mehdi Hamadani, Ambuj Kumar, et al.
Blood
|
October 4, 2024
Safety and efficacy of standard-of-care ciltacabtagene autoleucel for relapsed/refractory multiple myeloma
Surbhi Sidana, Krina K Patel, Lauren C Peres, et al.
Bone Marrow Transplantation
|
March 2, 2025
Chimeric antigen receptor T cell therapy in octogenarians with B cell lymphoma: a real-world US multicenter collaborative study
Mohamed A Kharfan-Dabaja, Razan Mohty, Neela Easwar, et al.
Transplantation and Cellular Therapy
|
August 28, 2021
American Society of Transplantation and Cellular Therapy, Center of International Blood and Marrow Transplant Research, and European Society for Blood and Marrow Transplantation Clinical Practice Recommendations for Transplantation and Cellular Therapies in Mantle Cell Lymphoma
Pashna N Munshi, Mehdi Hamadani, Ambuj Kumar, et al.
Blood Cancer Discovery
|
January 9, 2024
Baseline Serum Inflammatory Proteins Predict Poor CAR T Outcomes in Diffuse Large B-cell Lymphoma
Rawan G Faramand, Sae Bom Lee, Michael D Jain, et al.
Haematologica
|
July 10, 2025
Cytopenias and infections following ciltacabtagene autoleucel in heavily-pretreated relapsed or refractory multiple myeloma
Danai Dima, Jennifer M Logue, Syed Hamza Bin Waqar, et al.
Blood
|
June 11, 2026
Product-Intrinsic NF-κB-Driven Transcriptional Programs Connote Durability of CAR-T Response in Multiple Myeloma
Jerald D Noble, Barbara C Peixoto, Meghan A Menges, et al.
Blood Advances
|
August 8, 2022
Early cytopenias and infections after standard of care idecabtagene vicleucel in relapsed or refractory multiple myeloma
Jennifer M Logue, Lauren C Peres, Hamza Hashmi, et al.
Journal of Hematology & Oncology
|
August 6, 2024
Novel prognostic scoring systems for severe CRS and ICANS after anti-CD19 CAR T cells in large B-cell lymphoma
Pierre Sesques, Amy A Kirkwood, Mi Kwon, et al.
Page
of 20
Search research articles
Search
Showing results (171-180 of 195) with videos related to
Sort By:
Page
of 20
Frontiers in Immunology
|
December 3, 2025
Case Report: Durable response to tumor-infiltrating lymphocyte therapy in a patient with metastatic melanoma and chronic lymphocytic leukemia/small lymphocytic lymphoma
Lilit Karapetyan, Joel Kuriakose, Matthew C Perez, et al.
Bone Marrow Transplantation
|
August 20, 2021
ASTCT, CIBMTR, and EBMT clinical practice recommendations for transplant and cellular therapies in mantle cell lymphoma
Pashna N Munshi, Mehdi Hamadani, Ambuj Kumar, et al.
Blood
|
October 4, 2024
Safety and efficacy of standard-of-care ciltacabtagene autoleucel for relapsed/refractory multiple myeloma
Surbhi Sidana, Krina K Patel, Lauren C Peres, et al.
Bone Marrow Transplantation
|
March 2, 2025
Chimeric antigen receptor T cell therapy in octogenarians with B cell lymphoma: a real-world US multicenter collaborative study
Mohamed A Kharfan-Dabaja, Razan Mohty, Neela Easwar, et al.
Transplantation and Cellular Therapy
|
August 28, 2021
American Society of Transplantation and Cellular Therapy, Center of International Blood and Marrow Transplant Research, and European Society for Blood and Marrow Transplantation Clinical Practice Recommendations for Transplantation and Cellular Therapies in Mantle Cell Lymphoma
Pashna N Munshi, Mehdi Hamadani, Ambuj Kumar, et al.
Blood Cancer Discovery
|
January 9, 2024
Baseline Serum Inflammatory Proteins Predict Poor CAR T Outcomes in Diffuse Large B-cell Lymphoma
Rawan G Faramand, Sae Bom Lee, Michael D Jain, et al.
Haematologica
|
July 10, 2025
Cytopenias and infections following ciltacabtagene autoleucel in heavily-pretreated relapsed or refractory multiple myeloma
Danai Dima, Jennifer M Logue, Syed Hamza Bin Waqar, et al.
Blood
|
June 11, 2026
Product-Intrinsic NF-κB-Driven Transcriptional Programs Connote Durability of CAR-T Response in Multiple Myeloma
Jerald D Noble, Barbara C Peixoto, Meghan A Menges, et al.
Blood Advances
|
August 8, 2022
Early cytopenias and infections after standard of care idecabtagene vicleucel in relapsed or refractory multiple myeloma
Jennifer M Logue, Lauren C Peres, Hamza Hashmi, et al.
Journal of Hematology & Oncology
|
August 6, 2024
Novel prognostic scoring systems for severe CRS and ICANS after anti-CD19 CAR T cells in large B-cell lymphoma
Pierre Sesques, Amy A Kirkwood, Mi Kwon, et al.
Page
of 20